Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Human Exposomic Determinants of Immune Mediated Diseases

Descripción del proyecto

Vincular las enfermedades inmunitarias con exposiciones tempranas para unas soluciones innovadoras

El sistema inmunitario se encarga de protegernos contra los invasores. Cuando este sistema protector funciona mal, puede dañarnos en lugar de protegernos. La identificación errónea de intrusos inofensivos (como el polen o la caspa de las mascotas) como amenaza grave es lo que está detrás de las alergias y el asma. En las enfermedades autoinmunitarias como el lupus, la artritis reumatoide y la diabetes de tipo 1, el sistema inmunitario del cuerpo ataca y destruye células sanas. El proyecto HEDIMED, financiado con fondos europeos, investiga el papel del exposoma en las enfermedades inmunitarias. El exposoma es la suma de todas las «exposiciones» de una persona a productos químicos y al estrés en el vientre materno y a lo largo de su vida. HEDIMED estudia una amplia muestra clínica de mujeres embarazadas y niños, mediante la elaboración de perfiles moleculares y genéticos completos (ómica) y la extracción de datos para crear herramientas de acceso libre que potencien soluciones a este creciente reto para la salud pública.

Objetivo

Immune-mediated diseases (IMDs) are increasing rapidly in the developed countries constituting a huge medical, economic and societal challenge. The reasons to this epidemic are not known, but exposome needs to play an important role since genetic factors cannot explain such a rapid change. In the HEDIMED project altogether 20 academic and industrial partners will join their multidisciplinary and supplementary forces to identify exposomic determinants which are driving this epidemic. The project is based on a combination of data and biological samples from large clinical cohorts constituting the largest clinical resource in this field including 350.000 pregnant women, 28.000 children prospectively followed from birth and 6.600 children from cross-sectional studies. HEDIMED focuses on common chronic IMDs that cause a significant disease burden, including type 1 diabetes, celiac disease, allergies and asthma. Exposomic disease determinants and the underlying biological pathways will be identified by exploratory approach using advanced omics and multiplex technologies combined with cutting–edge datamining technologies. Particular emphasis is paid on early fetal and childhood exposome since the disease process is known to start early. Inclusion of several IMDs makes it possible to identify determinants that are common for many IMDs facilitating the development of widely operating treatments. HEDIMED includes also data and samples from clinical trials that have used exposomice interventions and cell and organ culture models to help the identification of causal associations. HEDIMED will generate an open-access toolbox that offers various kind of data, new technologies, interactions forums, latest information and functional tools for several stakeholders to facilitate the efforts to find ways to control the IMD epidemic. HEDIMED will generate several innovations which can become exploited widely in diagnostic, therapeutic, preventive and health-economical applications. HEDIMED will work together with the other projects (EXPANSE, HEAP, ATHLETE, EQUAL-LIFE, LONGITOOLS, EPHOR, REMEDIA and EXIMIOUS) funded within the Human Exposome programme call H2020 SC1-BHC-2018-2020, in order to achieve collaboration and synergy

Convocatoria de propuestas

H2020-SC1-BHC-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SC1-2019-Single-Stage-RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

TAMPEREEN KORKEAKOULUSAATIO SR
Aportación neta de la UEn
€ 1 562 782,50
Dirección
KALEVANTIE 4
33100 Tampere
Finlandia

Ver en el mapa

Región
Manner-Suomi Länsi-Suomi Pirkanmaa
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 562 782,50

Participantes (22)